Physician profile
Mark D Kosins
NPI 1457424954
$4,753.60
in general payments reported to CMS, 2019-2025
24 companies · $330 in 2025
The $330 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $829 · 2020: $635 · 2021: $895 · 2022: $532 · 2023: $883 · 2024: $650 · 2025: $330.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,863.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,862.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,137.19 | 2021-2025 | |
| Lundbeck LLC | $749.79 | 2019-2024 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $563.01 | 2019-2024 | Trintellix |
| Allergan, INC. | $375.24 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $373.93 | 2019-2025 | Fanapt, Hetlioz |
| Sunovion Pharmaceuticals INC. | $190.77 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $187.51 | 2020-2025 | Caplyta |
| Ironshore Pharmaceuticals INC. | $160.71 | 2019-2023 | Jornay Pm |
| Almatica Pharma LLC | $160.08 | 2024 | Loreev Xr |
| Alkermes, INC. | $146.98 | 2023-2025 | Lybalvi, Aristada |
| Idorsia Pharmaceuticals US INC | $136.55 | 2023-2024 | Quviviq |
| Supernus Pharmaceuticals, INC. | $87.00 | 2021-2023 | Qelbree |
| Harmony Biosciences LLC | $76.87 | 2020-2023 | Wakix |
| Janssen Pharmaceuticals, INC | $71.75 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $69.92 | 2025 | Cobenfy |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertical Pharmaceuticals, LLC | $59.91 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $50.47 | 2019-2022 | |
| Corium, LLC | $37.87 | 2023 | Azstarys |
| Eisai INC. | $24.92 | 2021 | |
| Gilead Sciences, INC. | $23.65 | 2019 | |
| Tris Pharma INC | $21.15 | 2023 | Dyanavel Xr |
| Axsome Therapeutics, INC. | $18.90 | 2024 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $15.19 | 2019 | |
| Bausch Health US, LLC | $14.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Kosins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.